Another court ruling this month could tip the balance further, and not in the FDA's favour. This case, United States v. Caronia, relates to the conviction of a pharmaceutical salesman for Orphan Medical (taken over in 2005 by Jazz Pharmaceuticals based in Dublin), who was recorded telling a potential client that the drug Xyrem (γ-hydroxybutyrate) could treat a variety of ills, including muscle disorders, chronic pain, Parkinson's disease and fibromyalgia. In fact, the drug had been approved by the FDA only for treating acute muscle weakness or excessive daytime sleepiness associated with narcolepsy. Xyrem can be abused and carries the FDA's strongest safety warning against use in children. In 2007, Jazz Pharmaceuticals agreed to a settlement of $20 million in fines and compensation payments for the off-label marketing of Xyrem by Orphan.